MRX-2843 is an orally available small molecule MERTK and FMS-like tyrosine kinase 3 (FLT3) inhibitor that has potent preclinical activity in B-ALL [16], acute myeloid leukemia [17], and solid tumor models [18] and is currently in phase I clinical trials in patients with solid tumors (NCT03510104 and NCT04762199) and leukemia (NCT04872478 and NCT04946890). This evidence concerns the gene FLT3 and leukemia.